Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Riccardo Tomasello *Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Via del Vespro 129, Palermo, 90127, Italy.ORCID http://orcid.org/0000-0002-0870-6097
Simona RasoHematology and Rare Diseases Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy. simona.raso86@gmail.com.ORCID http://orcid.org/0000-0002-0967-2191
Ombretta AnnibaliDivision of Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, Roma, Italy.ORCID http://orcid.org/0000-0002-3095-5313
Mariantonietta TafuriDivision of Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, Roma, Italy.
Marta MattanaDepartment of precision medicine in medical, surgical and critical care (Me.Pre.Cc), University of Palermo, Raffadali, Italy.ORCID http://orcid.org/0000-0001-6913-8268
Tania SorianoDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0009-0005-4772-3892
David FanciulloDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Giovanni Manfredi AssantoDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-6190-9635
Erminia BaldacciDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Eugenio SantacroceDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0009-0000-2898-5241
Manuela Giuseppa IngrascìDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Via del Vespro 129, Palermo, 90127, Italy.ORCID http://orcid.org/0009-0001-3993-2097
Mario BigliettoDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0003-1487-5812
Claudia CammarataDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Via del Vespro 129, Palermo, 90127, Italy.ORCID http://orcid.org/0000-0002-0195-9964
Matteo TotaroDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Silvio LigiaDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-2803-3766
Cristina SantoroDivision of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-7181-447X
Sergio SiragusaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Via del Vespro 129, Palermo, 90127, Italy.ORCID http://orcid.org/0000-0002-1641-6508
Mariasanta NapolitanoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Via del Vespro 129, Palermo, 90127, Italy. mariasanta.napolitano@unipa.it.ORCID http://orcid.org/0000-0001-8934-2936
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Rituximab is employed in the treatment of B-cell non-Hodgkin lymphomas (NHL) and autoimmune disorders of hematological interest (ADHI), such as autoimmune hemolytic anemia (AIHA), acquired hemophilia A (AHA), and immune thrombocytopenia (ITP). Rituximab induces profound B-cell depletion, reducing the titer of immunoglobulins and autoreactive antibodies, but secondary hypogammaglobulinemia increases risk of infections. We performed a retrospective, multicentric study across seven Italian centers to compare two cohorts of patients with either indolent NHL or ADHI treated with rituximab between March 2014 and March 2024. We evaluated the incidence and characteristics of infections and common antimicrobial prophylaxis adopted according to local clinical practice, in the absence of shared guidelines for ADHI. We included 285 patients (52% female; median age 55 years). The ADHI cohort comprised 187 patients (65%; 97 ITP, 78 AIHA, 12 AHA), while the control group included 98 i-NHL patients (34%). We documented 65 infectious events occurring in 65/285 patients (22.8%). Infection-related mortality occurred in 9 patients (4%). When stratified, the cumulative 180-day incidence of infections was 9.4% (IC95% 8.8%-10%) for NHL patients and 13.7% for ADHI (IC95% 12.2%-14.2%). Multivariate analysis identified prophylaxis (OR 2.62, p = 0.014) and post-treatment hypogammaglobulinemia (OR 2.73 p = 0.004) as risk factors. The risk of infection in patients with ADHI is high and comparable to that observed in NHL. Therefore, close monitoring of IgG levels is strongly advised, and mortality can be contained through rigorous antimicrobial stewardship.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma. · full record | OpenQuestion